Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 8/20 | 0.43 |
| ▸ | GAA | P10253 | 6/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 4/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 4/20 | 0.43 |
| ▸ | CYP2C19 | P33261 | 4/20 | 0.43 |
| ▸ | HPGD | P15428 | 3/20 | 0.43 |
| ▸ | MEN1 | O00255 | 2/20 | 0.43 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.43 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.40 |
| ▸ | HTT | P42858 | 1/20 | 0.40 |
| ▸ | THRB | P10828 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 3/20 | 0.39 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.39 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16007133 | 0.72 | ALDH1A1 (0.47) | ALDH1A1GAAKDM4EHPGDMEN1 | |
| SCHEMBL16056968 | 0.72 | HTT (0.44) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL31454201 | 0.72 | HTT (0.44) | ALDH1A1HPGDMEN1KMT2ASMN1; SMN2 | |
| SCHEMBL30590661 | 0.71 | ALDH1A1 (0.51) | ALDH1A1GAAKDM4ECYP1A2CYP2C9 | |
| SCHEMBL7441225 | 0.70 | ALDH1A1 (0.56) | ALDH1A1GAAKDM4ECYP1A2CYP2C9 | |
| SCHEMBL27149002 | 0.70 | SMN1; SMN2 (0.47) | ALDH1A1GAACYP3A4KMT2ASMN1; SMN2 | |
| SCHEMBL9194011 | 0.70 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4ECYP1A2HPGD | |
| SCHEMBL15561085 | 0.69 | ALDH1A1 (0.46) | ALDH1A1GAAKDM4ECYP1A2CYP2C9 | |
| SCHEMBL25361763 | 0.69 | ALDH1A1 (0.40) | ALDH1A1GAAKDM4ECYP1A2HPGD | |
| SCHEMBL23692936 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-B1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL MYERS SQUIBB CO (US) | 2016-12-21 | — | — | EP | disclosed |
| EP-2970296-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | Bristol-Myers Squibb Company (US) | 2016-01-20 | — | — | EP | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| US-9050345-B2 | Pyrrolotriazines as potassium ion channel inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2015-06-09 | — | — | US | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| WO-2014143610-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2014-09-18 | — | — | WO | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY | 2014-09-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140256719-A1 | PYRROLOTRIAZINES AS POTASSIUM ION CHANNEL INHIBITORS | KCNJ4, KCNJ2, KCNA4 | ALDH1A1 2596/4885GAA 4803/4885KDM4E 1004/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.